drugset / Trial / NCT07093411
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 0
Recruiting
48 enrolled
Beijing GoBroad Hospital
Anhui Provincial Hospital · collabFirst Affiliated Hospital of Wenzhou Medical University · collabSecond Affiliated Hospital of Xi'an Jiaotong University · collabThe Affiliated Hospital of Xuzhou Medical University · collabThe First Affiliated Hospital of Zhengzhou University · collab
NaSingle-groupOpen-labelTreatment
Summary
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-E9D,LUCAR-E9K, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Timeline
- Start
- 2025-08-05
- Primary completion
- 2028-08
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUCAR-E9D | Cell therapy | — | Other |
| Subject | LUCAR-E9K | Cell therapy | — | Other |